Tesamorelin - Growth Hormone-Releasing Hormone (GHRH) Analog

Tesamorelin for Research: Complete Scientific Overview

Tesamorelin (also known as TH9507) is a synthetic 44-amino acid peptide analog of human growth hormone-releasing hormone (GHRH), representing the full-length sequence of endogenous GHRH (1-44). Developed by Theratechnologies Inc., tesamorelin was specifically designed to overcome the rapid degradation of native GHRH while maintaining full receptor activation capability. Unlike shorter GHRH fragments such as sermorelin (GHRH 1-29), which truncates the C-terminal region, tesamorelin retains the complete structure of endogenous GHRH, potentially offering distinct pharmacokinetic and pharmacodynamic properties. The peptide has been extensively studied in over 2,000 research subjects across multiple clinical trials, with a particular focus on its effects on visceral adipose tissue (VAT), metabolic parameters, and the GH/IGF-1 axis. Tesamorelin received regulatory approval in 2010 for the treatment of HIV-associated lipodystrophy, making it one of the most thoroughly characterized GHRH analogs available for research applications.

Mechanism of Action

Tesamorelin exerts its biological effects through specific activation of the GHRH receptor on somatotroph cells:

• GHRH Receptor Activation (Primary Mechanism): Tesamorelin binds selectively to the GHRH receptor (GHRHR), a class B G-protein coupled receptor expressed on somatotroph cells in the anterior pituitary gland. Receptor activation stimulates the Gs protein signaling pathway, leading to adenylate cyclase activation, increased intracellular cAMP, and activation of protein kinase A (PKA). This signaling cascade promotes the synthesis and release of growth hormone (GH) from secretory granules.
• Pulsatile GH Stimulation: Tesamorelin triggers pulsatile release of endogenous growth hormone, closely mimicking the natural ultradian rhythm of GH secretion. This pulsatility is critical for maintaining the biological activity of GH at target tissues, as continuous GH exposure leads to receptor desensitization and reduced biological effects. The pulsatile pattern induced by tesamorelin is more physiological than continuous GH administration.
• IGF-1 Elevation: The GH released in response to tesamorelin stimulates hepatic production of insulin-like growth factor-1 (IGF-1), which mediates many of the growth-promoting and metabolic effects of GH. IGF-1 levels increase in a dose-dependent manner with tesamorelin administration, serving as a reliable biomarker of GH axis activation.
• Visceral Fat Reduction (Distinctive Property): Tesamorelin has demonstrated specific and pronounced effects on visceral adipose tissue (VAT) reduction in multiple research models. Unlike full-length hGH, which can cause insulin resistance and glucose intolerance, tesamorelin has shown beneficial effects on VAT without significantly affecting subcutaneous adipose tissue. This selective effect on VAT makes tesamorelin unique among GH axis modulators.
• Lipid Metabolism Modulation: Tesamorelin influences lipid metabolism through multiple mechanisms, including reductions in triglycerides, LDL cholesterol, and apolipoprotein B. These effects are mediated through GH-dependent and GH-independent pathways, involving increased fatty acid oxidation, reduced hepatic lipogenesis, and improved lipid clearance.
• Full-Length Structure Advantages: The complete 44-amino acid sequence of tesamorelin provides several advantages over truncated GHRH analogs. The C-terminal region (residues 30-44) contributes to receptor binding affinity, stability against proteolytic degradation, and potentially engages additional signaling pathways not activated by shorter fragments.

Research Significance and Clinical Validation

Tesamorelin has been the subject of extensive preclinical and clinical research, providing a robust foundation for its use as a research tool. Key findings from the literature include:

• Phase 3 clinical trials demonstrated significant reductions in visceral adipose tissue (VAT) with tesamorelin treatment (average reduction of 15-20% over 6 months).
• Improvements in lipid profiles, including reductions in triglycerides (median decrease of 49 mg/dL) and improvements in HDL cholesterol.
• No significant effects on glucose homeostasis or insulin sensitivity in most studies, distinguishing tesamorelin from full-length hGH.
• Demonstrated safety and tolerability in over 2,000 research subjects across multiple clinical trials.
• FDA approval for HIV-associated lipodystrophy in 2010, validating the peptide's pharmacological activity and safety profile.
• Well-characterized pharmacokinetics with a half-life of approximately 30-60 minutes following subcutaneous administration.

Research Applications

• Visceral Adipose Tissue (VAT) Research: Investigating the mechanisms of selective VAT reduction, including studies on adipocyte metabolism, lipolysis, fatty acid oxidation, and adipokine secretion.
• Growth Hormone/IGF-1 Axis Regulation: Studying the physiological regulation of the GH/IGF-1 axis, including pulsatile secretion patterns, feedback mechanisms, and age-related decline in GH secretion.
• Comparative GHRH Analog Pharmacology: Comparing the pharmacokinetic and pharmacodynamic properties of full-length GHRH (tesamorelin) versus truncated GHRH fragments (sermorelin, CJC-1295, Mod GRF 1-29).
• Metabolic Syndrome Research: Investigating the effects of GHRH agonism on metabolic parameters including glucose homeostasis, insulin sensitivity, lipid metabolism, and body composition.
• HIV-Associated Metabolic Research: Studying the pathophysiology of HIV-associated lipodystrophy and other metabolic complications, with tesamorelin as an established reference compound.
• Age-Related GH Decline Research: Investigating the age-associated decline in GHRH sensitivity and GH secretion, and potential interventions to restore physiological GH levels.
• Cardiometabolic Risk Factors: Studying the effects of GHRH activation on cardiovascular risk markers, including inflammatory cytokines, endothelial function, and vascular health.
• Liver Fat and Hepatic Steatosis: Investigating the effects of tesamorelin on intrahepatic lipid content, liver enzymes, and markers of non-alcoholic fatty liver disease (NAFLD).
• Hypothalamic-Pituitary Function: Understanding the central and peripheral regulation of the GH axis, including interactions with somatostatin, ghrelin, and other neuroendocrine factors.
• Pulsatility vs. Continuous GH Studies: Using tesamorelin to investigate the importance of pulsatile GH secretion versus continuous GH exposure on target tissue responses.
• Gender Differences in GH Response: Studying sex-based differences in GHRH sensitivity and GH secretion patterns.

Comparison with Other GHRH Analogs

• Tesamorelin (44 amino acids): Full-length GHRH (1-44). FDA-approved for HIV-associated lipodystrophy. Well-characterized effects on visceral fat reduction. Half-life ~30-60 minutes.
• Sermorelin (29 amino acids): Truncated GHRH (1-29). Shorter half-life, primarily studied for GH stimulation in GH deficiency. Less characterized for metabolic effects.
• CJC-1295 with DAC: Modified GHRH analog with Drug Affinity Complex (DAC) for extended half-life (~7-8 days). Produces sustained, non-pulsatile GH elevation.
• CJC-1295 no DAC (Mod GRF 1-29): Tetrasubstituted GHRH (1-29) with short half-life (~30 minutes). Designed for pulsatile GH release, lacks the C-terminal region.

Structural Characteristics

Tesamorelin is a 44-amino acid peptide with several key structural features:

• Full-Length GHRH Sequence: Represents the complete 44-amino acid sequence of endogenous human GHRH (1-44), unlike truncated fragments that lack the C-terminal region.
• C-Terminal Amidation: The C-terminal leucine is amidated, which enhances stability and biological activity compared to the free acid form.
• No Sequence Modifications: Unlike CJC-1295 (which contains four amino acid substitutions), tesamorelin maintains the native GHRH sequence, potentially reducing immunogenicity and maintaining native receptor binding characteristics.
• Complete Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

Chemical Information

CAS Number: 218949-48-5
Research Codes: TH9507, GHRH(1-44), Full-length GHRH analog, Tesamorelin acetate
Molecular Formula: C221H366N72O68S
Molecular Weight: 5135.8 g/mol
Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Number of Amino Acids: 44 (full-length)
Receptor Target: GHRH Receptor (GHRHR)
Half-Life: Approximately 30-60 minutes (subcutaneous administration)
Purity: >99% (HPLC)
Form: Lyophilized powder
Storage: -20°C (lyophilized), 4°C (reconstituted)
Stability: Stable at -20°C for 24 months; reconstituted solution stable at 4°C for 30 days

Reconstitution and Handling Protocols

For optimal stability and research validity, Tesamorelin should be reconstituted with sterile bacteriostatic water or sterile saline (0.9% NaCl). Allow the lyophilized powder to dissolve completely without vigorous shaking to maintain peptide integrity. Gently swirl the vial until the solution is clear and free of particulates. Once reconstituted, the solution should be stored at 4°C and used within 30 days. Avoid repeated freeze-thaw cycles to preserve peptide structure and biological activity. For long-term storage, keep the lyophilized powder at -20°C away from light and moisture. Do not vortex or vigorously shake the reconstituted solution, as this may cause aggregation and reduce GHRH receptor binding activity.

Quality Assurance

PeptideVanta's Tesamorelin undergoes rigorous quality control including HPLC purity analysis (>99%), ESI-mass spectrometry for molecular weight confirmation (expected 5135.8 Da), endotoxin testing (<1.0 EU/mg), sterility testing, and residual solvent analysis. Each batch is accompanied by a Certificate of Analysis (COA) with complete testing results. The peptide is synthesized using solid-phase peptide synthesis (SPPS) with Fmoc chemistry, followed by HPLC purification and lyophilization under sterile conditions.